COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
SUMMARY OF POSITIVE OPINION* for
CLOPIDOGREL KRKA

International Non-proprietary Name (INN): clopidogrel

On 25 June 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, ** recommending to grant a marketing authorisation for the medicinal product Clopidogrel Krka, 75 mg, film-coated tablets intended for use in adults for the prevention of atherothrombotic events in patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. The applicant for this medicinal product is Krka Novomesto.

The active substance of Clopidogrel Krka is clopidogrel (as hydrochloride), a platelet aggregation inhibitor excl. heparin medicinal product (B01AC04). Clopidogrel selectively inhibits the binding of ADP to its platelet receptor, and the subsequent ADP-mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation.

Clopidogrel Krka is a generic of Plavix. Studies have demonstrated the satisfactory quality of Clopidogrel Krka, and its bioequivalence with the reference product Plavix. A question-and-answer document on generic medicines can be found here.

The approved indication is as follows:
“Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.”

A pharmacovigilance plan for Clopidogrel Krka, as for all medicinal products, will be implemented as part of the marketing authorisation.

Detailed recommendations for the use of this product will be described in the Summary of Product Characteristics (SPC) which will be published in the European Public Assessment Report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit to risk balance for Clopidogrel Krka and therefore recommends the granting of the marketing authorisation.

---

* Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 67 days from adoption of the Opinion.
** Applicants may request a re-examination of any CHMP opinion, provided they notify the EMEA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.